Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xilio TherapeuticsXLO +1.05%32 EV-to-OCF is 1.54 as of Jul. 26, 2026, which is 191% above its 10-year median of 0.53. GuruFocus rates XLO with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Xilio Therapeutics ranks worse than 78.28% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Xilio Therapeutics's Enterprise Value is $-86.89 Mil.
Xilio Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-56.31 Mil. Therefore, Xilio Therapeutics's EV-to-OCF for today is 1.54.
The historical rank and industry rank for Xilio Therapeutics's EV-to-OCF or its related term are showing as below:
XLO'
s EV-to-OCF Range Over the Past 10 Years
Min: -2.22 Med: 0.53 Max: 10.62
Current: 1.54
During the past 7 years, the highest EV-to-OCF of Xilio Therapeutics was 10.62. The lowest was -2.22. And the median was 0.53.
XLO's EV-to-OCF is ranked worse than 78.28% of 1409
companies
in the Biotechnology industry
Industry Median: -3.29
vs XLO: 1.54
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xilio Therapeutics's PE Ratio (TTM) for today is calculated as:
Xilio Therapeutics's share price for today is $8.64.
Xilio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Xilio Therapeutics EV-to-OCF Related Terms
Xilio Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Xilio Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xilio Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xilio Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Xilio Therapeutics's EV-to-OCF falls into.
Xilio Therapeutics's current Enterprise Value is $-86.89 Mil.
Xilio Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xilio Therapeutics (XLO) has a EV-to-OCF of 1.54 as of Jul. 26, 2026. This is 191% above median its historical median of 0.53. According to the industry distribution chart, Xilio Therapeutics ranks #1103 out of 1409 companies in the Biotechnology industry, placing it in the top 78.3%.
Is Xilio Therapeutics' EV-to-OCF too high?
Xilio Therapeutics' current EV-to-OCF of 1.54 is 191% above median its 10-year median of 0.53. Based on the distribution chart, Xilio Therapeutics ranks #1103 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xilio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Xilio Therapeutics' EV-to-OCF compare to FLNA and BSEM?
According to the Biotechnology industry distribution chart, Xilio Therapeutics ranks #1103 out of 1409 companies for EV-to-OCF. This places Xilio Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Xilio Therapeutics's current EV-to-OCF is 1.54, which is 191% above median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xilio Therapeutics stock overvalued right now?
Xilio Therapeutics (XLO) has a current EV-to-OCF of 1.54. The current EV-to-OCF is 1.54, which is 191% above median its 10-year median of 0.53. Xilio Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Xilio Therapeutics (XLO), the current EV-to-OCF is 1.54 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
32GF Score
Get the complete analysis for XLO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XLO has been successfully added to your 
